Morningstar

Zoetis Inc Class A ZTS

Morningstar Rating
Unlock
Stock XNYS Rating as of
$195.02 +0.27 (0.14%)
View Full Chart
As of Cboe BZX Real-Time Price Open

Company Report

View Archive

Zoetis Reinforces Its Wide Economic Moat With Innovative Companion Animal Therapies

Debbie S. Wang

Zoetis is the undisputed leader in the global animal health industry, and we believe it possesses the widest moat of all the competitors. Zoetis has set itself apart based on its impressive innovation that shows up across its product portfolio, including a number of drugs for specific pet ailments such as separation anxiety. The firm has also sought to expand its presence into virtually every type of animal-related health market, including aquaculture and pet diagnostics.

Read Full Report

Price vs Fair Value

View History
ZTS is trading at a 680% premium.
Price
$194.81
Fair Value
$454.00
Uncertainty
Medium
1-Star Price
$787.90
5-Star Price
$999.00
Economic Moat
Rpl
Capital Allocation
Khrvmhff

Bulls Say, Bears Say

Bulls

Growing interest in probiotics, antibacterial peptides, and immune modulators as alternatives to antibiotics offer many targets for innovation.

Bears

Strict regulation or restriction of antibiotic use in animals could harm Zoetis' production-animal product sales.

Show More

News

View All

Trading Information

Previous Close Price
$194.75
Day Range
$193.68–195.76
52-Week Range
$144.80–201.91
Bid/Ask
$194.94 / $195.11
Market Cap
$88.35 Bil
Volume/Avg
409,442 / 1.9 Mil

Key Statistics

Price/Earnings (Normalized)
35.16
Price/Sales
10.03
Dividend Yield (Trailing)
0.86%
Dividend Yield (Forward)
0.89%
Total Yield
2.40%

Company Profile

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Large Core
Total Number of Employees
14,100
Website
https://www.zoetis.com

Competitors

Valuation

View More
Metric
ZTS
LLY
MRK
Price/Earnings (Normalized)
 35.1678.6517.46
Price/Book Value
 17.8058.286.61
Price/Sales
 10.0320.384.64
Price/Cash Flow
 30.5979.0315.45
Price/Earnings
ZTS
LLY
MRK

Financial Strength

Metric
ZTS
LLY
MRK
Quick Ratio
 1.640.610.88
Current Ratio
 3.451.111.47
Interest Coverage
 12.6815.0813.07
Quick Ratio
ZTS
LLY
MRK

Profitability

Metric
ZTS
LLY
MRK
Return on Assets (Normalized)
 18.00%13.15%15.46%
Return on Equity (Normalized)
 51.43%69.16%41.15%
Return on Invested Capital (Normalized)
 22.69%23.97%22.92%
Return on Assets
ZTS
LLY
MRK

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Merck KGaA ADR
MKKGY
BhpdxsvbdNnblpy$78.0 Bil
 Haleon PLC ADR
HLN
LzdzpsmxMby$48.4 Bil
 Viatris Inc
VTRS
XcvvtgzhWgd$13.8 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
SmpxdqlffBrnj$13.5 Bil
 Catalent Inc
CTLT
FjjrqcmcWdbrpp$10.9 Bil
 Prestige Consumer Healthcare Inc
PBH
FqmjfwzyjCpjnbd$3.5 Bil
 Perrigo Co PLC
PRGO
PqhvpsrfxQgcj$3.5 Bil
 Green Thumb Industries Inc
GTBIF
HlbhmksdFrdsv$2.5 Bil
 Curaleaf Holdings Inc
CURLF
MjkvhhbblPqyl$2.3 Bil

Sponsor Center